MoonLake Immunotherapeutics shares are trading higher on continued upward momentum after the company announced on Monday its Phase 2 study for Nanobody sonelokimabint met its primary endpoint in hidradenitis suppurativa. Also, Barclays raised its price target from $28 to $41.
Portfolio Pulse from Benzinga Newsdesk
MoonLake Immunotherapeutics shares are trading higher after announcing that its Phase 2 study for Nanobody sonelokimab met its primary endpoint in hidradenitis suppurativa.
June 27, 2023 | 3:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MoonLake Immunotherapeutics' stock is trading higher after positive results from its Phase 2 study for Nanobody sonelokimab in hidradenitis suppurativa.
The positive results from the Phase 2 study for Nanobody sonelokimab in hidradenitis suppurativa indicate that the company's product is showing promise, which can lead to increased investor confidence and a higher stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100